Abbreviations used in clinical trials: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<div style="-moz-column-count:4; column-count:4;"> | <div style="-moz-column-count:4; column-count:4;"> | ||
== A == | |||
[[Ankle brachial pressure index|ABI Ankle-brachial index]] | |||
[[ACC|ACC American College of Cardiology]] | |||
ACC American College of Cardiology | |||
ACS Acute coronary syndrome | ACS Acute coronary syndrome | ||
| Line 25: | Line 25: | ||
ATP Adult Treatment Panel | ATP Adult Treatment Panel | ||
== B == | |||
BMI Body mass index | BMI Body mass index | ||
BUN Blood urea nitrogen | BUN Blood urea nitrogen | ||
== C == | |||
CABG Coronary artery bypass graft | CABG Coronary artery bypass graft | ||
| Line 53: | Line 55: | ||
CVD Cardiovascular disease | CVD Cardiovascular disease | ||
== D == | |||
DHA Docosahexaenoic acid | DHA Docosahexaenoic acid | ||
DMC Data Monitoring Committee | DMC Data Monitoring Committee | ||
== E == | |||
EC Independent Ethics Committee | EC Independent Ethics Committee | ||
| Line 71: | Line 75: | ||
EU European Union | EU European Union | ||
== F == | |||
FBG Fasting blood glucose | FBG Fasting blood glucose | ||
| Line 77: | Line 82: | ||
FSH Follicle-stimulating hormone | FSH Follicle-stimulating hormone | ||
== G == | |||
GCP Good Clinical Practice | GCP Good Clinical Practice | ||
| Line 85: | Line 91: | ||
GWAS Genome-wide association study | GWAS Genome-wide association study | ||
== H == | |||
HbA1c Hemoglobin A1c | HbA1c Hemoglobin A1c | ||
| Line 105: | Line 112: | ||
HTG Hypertriglyceridemia | HTG Hypertriglyceridemia | ||
== I == | |||
ICF Informed consent form | ICF Informed consent form | ||
| Line 121: | Line 129: | ||
IWRS Interactive Web Response System | IWRS Interactive Web Response System | ||
== J == | |||
JAS Japanese Atherosclerosis Society | JAS Japanese Atherosclerosis Society | ||
== L == | |||
LBBB Left bundle branch block | LBBB Left bundle branch block | ||
| Line 133: | Line 143: | ||
LVH Left ventricle hypertrophy | LVH Left ventricle hypertrophy | ||
== M == | |||
MACE Major adverse coronary event | MACE Major adverse coronary event | ||
| Line 139: | Line 150: | ||
mITT Modified Intent-to-Treat | mITT Modified Intent-to-Treat | ||
== N == | |||
NCEP National Cholesterol Education Program | NCEP National Cholesterol Education Program | ||
| Line 147: | Line 159: | ||
NSTE-ACS Non-ST-segment elevation acute coronary syndrome | NSTE-ACS Non-ST-segment elevation acute coronary syndrome | ||
== O == | |||
O3FA Omega-3 fatty acid | O3FA Omega-3 fatty acid | ||
| Line 155: | Line 168: | ||
OR Odds ratio | OR Odds ratio | ||
== P == | |||
PAD Peripheral arterial disease | PAD Peripheral arterial disease | ||
| Line 169: | Line 183: | ||
PVD Peripheral vascular disease | PVD Peripheral vascular disease | ||
== R == | |||
RBC Red blood cells | RBC Red blood cells | ||
| Line 175: | Line 190: | ||
RR Relative risk | RR Relative risk | ||
== S == | |||
SAE Serious adverse event | SAE Serious adverse event | ||
| Line 184: | Line 200: | ||
SUSAR Suspected unexpected serious adverse reaction | SUSAR Suspected unexpected serious adverse reaction | ||
== T == | |||
TC Total cholesterol | TC Total cholesterol | ||
| Line 195: | Line 212: | ||
TIMI Thrombolysis In Myocardial Infarction | TIMI Thrombolysis In Myocardial Infarction | ||
== U == | |||
ULN Upper limit of normal | ULN Upper limit of normal | ||
| Line 201: | Line 219: | ||
USPI United States Prescribing Information | USPI United States Prescribing Information | ||
== V == | |||
VLDL-C Very low density lipoprotein cholesterol | VLDL-C Very low density lipoprotein cholesterol | ||
== W == | |||
WBC White cell blood count | WBC White cell blood count | ||
Revision as of 17:42, 27 October 2019
A
ACC American College of Cardiology
ACS Acute coronary syndrome
AE Adverse event
AHA American Heart Association
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase
AP Angina pectoris
apo B Apolipoprotein B
APOC3 Apolipoprotein C3
AST Aspartate aminotransferase
ATP Adult Treatment Panel
B
BMI Body mass index
BUN Blood urea nitrogen
C
CABG Coronary artery bypass graft
CAD Coronary artery disease
CBC Complete blood count
CEC Clinical Endpoint Committee
CHD Coronary heart disease
CHF Congestive heart failure
CI Confidence interval
CK-MB Creatine kinase-MB fraction
CrCL Creatinine clearance
CRF Case report form
CV Cardiovascular
CVD Cardiovascular disease
D
DHA Docosahexaenoic acid
DMC Data Monitoring Committee
E
EC Independent Ethics Committee
ECG Electrocardiogram
EDC Electronic data capture
eGRF Estimated glomerular filtration rate
EPA Eicosapentaenoic acid
Ethyl-EPA ethyl eicosapentaenoic acid
EU European Union
F
FBG Fasting blood glucose
FDA United States Food and Drug Administration
FSH Follicle-stimulating hormone
G
GCP Good Clinical Practice
GGT Gamma-glutamyl transferase
GMP Good Manufacturing Practice
GWAS Genome-wide association study
H
HbA1c Hemoglobin A1c
Hct Hematocrit
HDL-C High-density lipoprotein cholesterol
HF Heart failure
Hgb Hemoglobin
HIV Human immunodeficiency virus
HR Hazard ratio
hs-CRP High-sensitivity C-reactive protein
hsTnT High-sensitivity troponin T
HTG Hypertriglyceridemia
I
ICF Informed consent form
ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
IFCC International Federation of Clinical Chemistry
IMP Investigational medicinal product
IQR Interquartile range
IRB Institutional Review Board
ITT Intent-to-Treat
IWRS Interactive Web Response System
J
JAS Japanese Atherosclerosis Society
L
LBBB Left bundle branch block
LDL-C Low-density lipoprotein cholesterol
LOE Lack of efficacy
LpPLA2 Lipoprotein-associated phospholipase A2
LVH Left ventricle hypertrophy
M
MACE Major adverse coronary event
MI Myocardial infarction or mitral insufficiency
mITT Modified Intent-to-Treat
N
NCEP National Cholesterol Education Program
NGSP National Glycohemoglobin Standardization Program
NMR Nuclear magnetic resonance
NSTE-ACS Non-ST-segment elevation acute coronary syndrome
O
O3FA Omega-3 fatty acid
ODIS Off drug in stud y OGTT Oral glucose tolerance test
OR Odds ratio
P
PAD Peripheral arterial disease
PCI Percutaneous coronary intervention
PCSK9 Proprotein convertase subtilisin kexin 9
PH Proportional hazard
PI Principal Investigator
PP Per protocol
PVD Peripheral vascular disease
R
RBC Red blood cells
RLP-C Remnant lipoprotein cholesterol
RR Relative risk
S
SAE Serious adverse event
SAP Statistical Analysis Plan
SC Steering Committee
SPC Summary of Product Characteristics
SUSAR Suspected unexpected serious adverse reaction
T
TC Total cholesterol
TEAE Treatment-emergent adverse event
TG Triglycerides
TIA Transient Ischemic Attack
TIMI Thrombolysis In Myocardial Infarction
U
ULN Upper limit of normal
US United States
USPI United States Prescribing Information
V
VLDL-C Very low density lipoprotein cholesterol
W
WBC White cell blood count